Celltrion today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted positive opinions and recommended marketing authorisations ...

Vabysmo has demonstrated rapid and robust vision and anatomical improvements in neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME) and retinal vein occlusion (RVO) The ...

Andrew Kadis from Cambridge Vision Technology guides us through imaging technologies for retinal biomarkers in Alzheimer’s ...

Germany: A recent cross-sectional study has revealed a significant link between choriocapillaris flow deficit (CC FD%) and ...

Real-World Indian Data Confirms Safety of Lupin's Ranieyes for various Chorioretinal Vascular Disease Ranibizumab (Ranieyes) ...

Exegenesis Bio, a clinical stage global gene therapy company is pleased to announce that US FDA has granted Orphan Drug Designation (“ODD”) to EXG110, a novel gene therapy for Fabry disease, a rare ...

On November 18, 2024, Samsung Bioepis announced that the European Commission (EC) has approved its aflibercept biosimilar, OPUVIZ.

SOL-1 is the first registrational trial for AXPAXLI™ in wet AMDTopline clinical data from SOL-1 expected in Q4 2025Active clinical trial sites ...

In the third case, moderator Lisa J. Faia, MD presents her case of persistently active central retinal vein occlusion (CRVO), explaining her approach to switching this treatment-resistant patient to a ...

What are developmental venous anomalies? A developmental venous anomaly (DVA) is a problem with the way small veins are arranged. They may look like the spokes of a wheel. The veins drain into a ...